304 related articles for article (PubMed ID: 28869928)
1. Atypical Uterine Smooth Muscle Tumors: A Retrospective Evaluation of Clinical and Pathologic Features.
Maltese G; Fontanella C; Lepori S; Scaffa C; Fucà G; Bogani G; Provenzano S; Carcangiu ML; Raspagliesi F; Lorusso D
Oncology; 2018; 94(1):1-6. PubMed ID: 28869928
[TBL] [Abstract][Full Text] [Related]
2. Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
Petrović D; Babić D; Forko JI; Martinac I
Coll Antropol; 2010 Mar; 34(1):93-7. PubMed ID: 20437637
[TBL] [Abstract][Full Text] [Related]
3. Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential.
O'Neill CJ; McBride HA; Connolly LE; McCluggage WG
Histopathology; 2007 Jun; 50(7):851-8. PubMed ID: 17543074
[TBL] [Abstract][Full Text] [Related]
4. Immunoexpression of progesterone receptor, epithelial growth factor receptor and galectin-3 in uterine smooth muscle tumors.
Soltan MM; Albasry AM; Eldosouky MK; Abdelhamid HS
Cell Mol Biol (Noisy-le-grand); 2018 Apr; 64(5):7-12. PubMed ID: 29729689
[TBL] [Abstract][Full Text] [Related]
5. MIB-1 (Ki-67), p53, estrogen receptor, and progesterone receptor expression in uterine smooth muscle tumors.
Mittal K; Demopoulos RI
Hum Pathol; 2001 Sep; 32(9):984-7. PubMed ID: 11567229
[TBL] [Abstract][Full Text] [Related]
6. Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors.
Gökaslan H; Türkeri L; Kavak ZN; Eren F; Sişmanoğlu A; Ilvan S; Durmuşoğlu F
Gynecol Obstet Invest; 2005; 59(1):36-40. PubMed ID: 15377824
[TBL] [Abstract][Full Text] [Related]
7. Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
Bodner-Adler B; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2005 Jan; 96(1):62-6. PubMed ID: 15589581
[TBL] [Abstract][Full Text] [Related]
8. EMMPRIN (CD147) Expression in Smooth Muscle Tumors of the Uterus.
Kefeli M; Yildiz L; Gun S; Ozen FZ; Karagoz F
Int J Gynecol Pathol; 2016 Jan; 35(1):1-7. PubMed ID: 26352545
[TBL] [Abstract][Full Text] [Related]
9. Combination of MCM2 With Ki67 and p16 Immunohistochemistry Can Distinguish Uterine Leiomyosarcomas.
Keyhanian K; Lage JM; Chernetsova E; Sekhon H; Eslami Z; Islam S
Int J Gynecol Pathol; 2020 Jul; 39(4):354-361. PubMed ID: 32515921
[TBL] [Abstract][Full Text] [Related]
10. Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
Bodner-Adler B; Nather A; Bodner K; Czerwenka K; Kimberger O; Leodolter S; Mayerhofer K
Gynecol Oncol; 2006 Oct; 103(1):186-9. PubMed ID: 16595146
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of progesterone receptor and p53 expression in uterine smooth muscle tumors.
Hewedi IH; Radwan NA; Shash LS
Diagn Pathol; 2012 Jan; 7():1. PubMed ID: 22217299
[TBL] [Abstract][Full Text] [Related]
12. Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
Ip PP; Cheung AN; Clement PB
Am J Surg Pathol; 2009 Jul; 33(7):992-1005. PubMed ID: 19417585
[TBL] [Abstract][Full Text] [Related]
13. Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma.
Leitao MM; Soslow RA; Nonaka D; Olshen AB; Aghajanian C; Sabbatini P; Dupont J; Hensley M; Sonoda Y; Barakat RR; Anderson S
Cancer; 2004 Sep; 101(6):1455-62. PubMed ID: 15316901
[TBL] [Abstract][Full Text] [Related]
14. Uterine leiomyosarcoma arising in leiomyoma: clinicopathological study of four cases and literature review.
Yanai H; Wani Y; Notohara K; Takada S; Yoshino T
Pathol Int; 2010 Jul; 60(7):506-9. PubMed ID: 20594271
[TBL] [Abstract][Full Text] [Related]
15. P16, Ki67, P53, and WT1 Expression in Uterine Smooth Muscle Tumors: An Adjunct in Confirming the Diagnosis of Malignancy in Ambiguous Cases.
Delgado B; Dreiher J; Braiman D; Meirovitz M; Shaco-Levy R
Int J Gynecol Pathol; 2021 May; 40(3):257-262. PubMed ID: 32897968
[TBL] [Abstract][Full Text] [Related]
16. The Clinicopathological Study of 21 Cases With Uterine Smooth Muscle Tumors of Uncertain Malignant Potential: Centralized Review Can Purify the Diagnosis.
Basaran D; Usubutun A; Salman MC; Narin MA; Boyraz G; Turkmen O; Comert Kimyon G; Karalok A; Bulbul D; Turan T; Ozgul N; Yuce K
Int J Gynecol Cancer; 2018 Feb; 28(2):233-240. PubMed ID: 29303932
[TBL] [Abstract][Full Text] [Related]
17. The selected biomarker analysis in 5 types of uterine smooth muscle tumors.
Zhang Q; Kanis MJ; Ubago J; Liu D; Scholtens DM; Strohl AE; Lurain JR; Shahabi S; Kong B; Wei JJ
Hum Pathol; 2018 Jun; 76():17-27. PubMed ID: 29258902
[TBL] [Abstract][Full Text] [Related]
18. Bcl-2 receptor expression in patients with uterine smooth muscle tumors: an immunohistochemical analysis comparing leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma.
Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Mayerhofer K
J Soc Gynecol Investig; 2004 Apr; 11(3):187-91. PubMed ID: 15051039
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
Chen L; Yang B
Int J Gynecol Pathol; 2008 Jul; 27(3):326-32. PubMed ID: 18580309
[TBL] [Abstract][Full Text] [Related]
20. Estrogen and progesterone receptors expression in uterine malignant smooth muscle tumors: correlation with clinical outcome.
Raspollini MR; Amunni G; Villanucci A; Boddi V; Simoni A; Taddei A; Taddei GL
J Chemother; 2003 Dec; 15(6):596-602. PubMed ID: 14998087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
